Curaleaf – Aurora Hostile Bid Heats Up Further
In the latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down the latest twist in the Curaleaf–Aurora hostile takeover fight, plus a hemp email making the rounds that isn’t quite as clean as it sounds, before closing with the weekly Vantage Standard segment on the barriers to international expansion.
Aurora Cannabis (TSX: ACB) (NASDAQ: ACB) responded today to Curaleaf’s (TSX: CURA) (OTCQX: CURLF) hostile takeover bid, with Executive Chairman and CEO Miguel Martin urging shareholders to take no action while a special committee reviews the US$4.00-per-share offer. Martin pushed back on Curaleaf’s claim that Aurora refused to engage privately, and accused Curaleaf of going public specifically to pressure shareholders into a short-term decision to acquire Aurora’s strategic EU-GMP facilities at the lowest price possible. We debate the standoff: while we respect Martin’s medical-only turnaround, we make the case that Curaleaf is Aurora’s natural partner and entry point to the U.S. ahead of reform — and that if the bid truly undervalues Aurora, a competing offer should emerge.
The hosts then switch to an email from Brett Worley, CEO of MC Nutraceuticals, claiming hemp’s protection is now written into the Senate’s base bill text through December 11 — covering flower, delta-8, delta-9, HHC, and isolates under today’s rules. We break down what’s accurate and what’s being oversold: the House hasn’t voted yet, and compounds like delta-8 and HHC aren’t naturally derived — they’re synthetic conversions, making this another loophole-within-a-loophole. Flowhub CEO Kyle Sherman drops in to weigh in, arguing federal inaction and near-impossible enforcement are the root problems, and to show off Flowhub’s new Text-to-Order AI feature — “like texting your plug” — alongside a riff on AI budtenders and kiosks.
In the final segment, the Vantage Standard segment continues with COO Deepank Utkhede and Director of Sales Christian Santi, centered on Vantage’s extension of its TGA approval in Australia — not a new approval, but proof of an already-trusted, ongoing relationship with one of the world’s toughest regulators. They break down what CGMP compliance demands on a continuous basis, how certifications like TGA and ICH Q7 and a DEA Schedule I license each unlock different high-barrier global markets, and why building from scratch can take 18 to 24 months or more — positioning Vantage as a partner of choice for major pharmaceutical players seeking reliable cannabinoid manufacturing.
Catch all three segments on today’s episode.
